多西他赛联合卡培他滨治疗复发转移乳腺癌的不良反应分析及药学监护  

Analysis of adverse reactions of docetaxel combined with capecitabine in the treatment of recurrent and metastatic breast cancer and pharmaceutical care

作　　者：林玉燕 

机构地区：[1]广东省茂名石化医院东院区门诊药房,525000

出　　处：《中国现代药物应用》2014年第14期9-11,共3页Chinese Journal of Modern Drug Application

摘　　要：目的探究多西他赛联合卡培他滨治疗复发转移乳腺癌的不良反应及药学监护,研究药学监护的应用价值。方法 80例复发转移乳腺癌患者,按数字法随机分为观察组与对照组各40例,观察组给予多西他赛联合卡培他滨治疗,并由临床药师进行药学监护。对照组给予多西他赛联合卡培他滨治疗。观察两组患者不良反应情况及满意度。结果观察组患者中出现白细胞减少、手足综合征、血小板减少、恶心呕吐、迟发型腹泻、脱发等情况明显少于对照组,差异有统计学意义(P<0.05);观察组患者满意度明显高于对照组,差异有统计学意义(P<0.05)。结论多西他赛联合卡培他滨治疗复发转移乳腺癌临床效果确切,且进行药学监护能给患者进行针对性指导,有效降低不良反应的发生,提高患者的满意度,值得在临床上推广与应用。Objective To explore adverse reactions and pharmaceutical care of docetaxel combined with capecitabine in the treatment of recurrent and metastatic breast cancer to study the application value of the pharmaceutical care. Methods Divided 80 cases of recurrent and metastatic breast cancer patients into observation group and control group according to the digital method, 40 cases in each group, observation group was given docetaxel combined with capecitabine treatment, and pharmacist pharmaceutical care, control group was given docetaxel combined with capecitabine treatment only. Observed the satisfaction and adverse reactions of two groups. Results Syndrome of leukopenia, hands and feet syndrome, thrombocytopenia, diarrhea, nausea, vomiting, late onset, hair loss, and so on in the observation group were significantly less than the control group, the difference was statistically significant（P〈0.05）; observation group had significantly higher satisfaction, the difference was statistically significant（P〈0.05）. Conclusion Docetaxel combined with capecitabine in the treatment of recurrent and metastatic breast cancer has a precis clinical effect, and pharmaceutical care gives specific guidance to patients, which can effectively reduce the occurrence of adverse reactions, improve patients satisfaction, so it is worthy of popularization and application in clinic.

关 键 词：多西他赛 卡培他滨 复发转移乳腺癌 药学监护 

分 类 号：R737.9[医药卫生—肿瘤]